F-1/A: HengHong Technology Files IPO Amid Revenue Decline

HengHong Technology Inc., a Cayman Islands holding company distributing medical and health products in China, filed an amendment for its initial public offering of 2 million ordinary shares on Nasdaq, despite a significant revenue and net income decline in 2024.

Summary

• HengHong Technology Inc. is offering 2,000,000 ordinary shares in its initial public offering, with an expected price range of $4 to $6 per share.
• The company plans to list its ordinary shares on the Nasdaq Capital Market under the symbol HCPC.
• Total revenues decreased by 24.1% from RMB 264,117,663 in 2023 to RMB 200,359,043 (US$ 27,449,077) in 2024.
• Net income decreased by 31.9% from RMB 22,387,571 in 2023 to RMB 15,240,356 (US$ 2,087,921) in 2024.
• The decline in revenue was primarily due to a 32.9% decrease in sales of Traditional Chinese Medicines (TCMD) as demand returned to normal after the COVID-19 surge in 2023 and a slowdown in the Chinese economy.
• Sales of chemical medicines increased by 17.9% in 2024 due to active marketing of the product 'Anlong'.
• The company started procurement and sales of TCMD raw materials in 2024, generating RMB 4,930,372 in revenue from this new category.
• Gross profit decreased by 27.3% to RMB 44,597,775 in 2024, with the gross profit margin slightly declining from 23.2% to 22.3%.
• General and administrative expenses increased by 58.7% in 2024, mainly due to professional fees incurred during IPO preparation.
• Government subsidies significantly increased from RMB 110,000 in 2023 to RMB 5,020,045 (US$ 687,743) in 2024.
• The company is a Cayman Islands holding company, with its primary operations conducted through subsidiaries in mainland China, particularly Hainan HengCheng Health Industrial Co., Ltd.
• HengHong Technology Inc. will be a controlled company under Nasdaq rules, with Mr. Weixiong Tan, the Chairman, owning 74.6% of outstanding shares post-IPO (assuming no over-allotment).

Sentiment

Score: 4

Explanation: The company faces significant financial declines in revenue and net income, coupled with extensive regulatory and operational risks related to its China-based operations and IPO process. While it has clear growth strategies and a strong market position in its niche, the current financial performance and the multitude of risks present a cautious outlook.

Positives

• The company has an experienced and stable marketing team, with over 80% of staff having more than 10 years of experience in medicine sales.
• A well-developed multi-channel sales system, including offline and online distribution, covers 22 provinces and autonomous regions in China.
• Strong product marketing capabilities focus on hospitals, retail pharmacies, and community clinics, assisting distributors in sales.
• An efficient 'light-asset' operational model reduces capital costs by managing inventory through sales-based procurement and strictly managing accounts receivable credit periods.
• The company is actively responding to market changes by increasing online marketing activities and expanding into pharmaceutical e-commerce.
• Significant increase in government subsidies received in 2024, totaling RMB 5,020,045 (US$ 687,743).
• Cash and cash equivalents increased from RMB 5,172,306 in 2023 to RMB 7,272,090 (US$ 996,272) in 2024.
• Short-term bank borrowings decreased by 56.2% from RMB 36,935,055 in 2023 to RMB 16,175,932 (US$ 2,216,094) in 2024.
• The company has received all required permissions from Chinese authorities to operate its current business in China, including business, bank account, medicine operation, and food operation permits.

Negatives

• Total revenues decreased by 24.1% year-over-year, from RMB 264,117,663 in 2023 to RMB 200,359,043 in 2024.
• Net income decreased by 31.9% year-over-year, from RMB 22,387,571 in 2023 to RMB 15,240,356 in 2024.
• Sales of Traditional Chinese Medicines (TCMD) decreased by 32.9% in 2024, attributed to dissipating COVID-19 demand and a slowdown in the Chinese economy.
• Gross profit margin slightly decreased from 23.2% in 2023 to 22.3% in 2024.
• General and administrative expenses increased by 58.7% in 2024, partly due to IPO-related professional fees.
• The company relies heavily on a single related-party vendor, Guangdong HengCheng Pharmaceutical Co., Ltd. (GDHC), for 96.5% of its product purchases in 2024, posing concentration risk.
• The company does not carry any business interruption insurance, product liability insurance, or other business insurance policies, exposing it to uninsured losses.
• A long-term bank loan of RMB 12,000,000 became callable as of December 31, 2023, due to violation of certain restrictive terms and financial covenants related to the company's reorganization for the IPO.

Risks

• Subject to risks related to public health crises such as COVID-19, which impacted sales and supply chains.
• Exposure to significant liability claims or complaints from customers, doctors, patients, or hospitals, litigation, and regulatory investigations related to medical product safety.
• Reliance on a limited number of vendors, with GDHC accounting for 96.5% of total product purchases in 2024, and 100% of advance payments to suppliers.
• Dependence on sourcing and distributing new products and maintaining markets for existing products, subject to rapid market changes and customer demand shifts.
• Uncertain economic or social conditions in China may adversely impact demand for products or cause financial hardship for customers and partners.
• Significant changes in customer relationships or demand could impact business, especially with potential customer concentration.
• Reputation erosion due to product recalls, litigation, defects, or negative publicity could materially impact financial results.
• Reliance on third parties (suppliers, distributors, banks) creates additional operational and financial risks.
• Disruptions in the supply chain, including labor disputes, natural disasters, or acts of war, could adversely impact product supply.
• Cost fluctuations, particularly in product purchase prices, labor, transportation, and energy, could affect business results.
• Potential for increased scrutiny, criticism, and negative publicity involving U.S.-listed China-based companies, leading to significant resource expenditure and stock price decline.
• Growing competition in China's medical and health products markets from more seasoned companies with greater resources.
• Expansion into new product categories exposes the company to new challenges, including unfamiliarity with demand, inventory buildup, quality issues, and potential lower profit margins.
• May incur net losses in the future, especially with increased expenses for new products and business development.
• Need for additional capital, which may not be available on acceptable terms or at all, leading to dilution or increased fixed obligations.
• Potential for substantial debt in the future, which may adversely affect financial condition and operations.
• Interim results may fluctuate significantly and may not fully reflect underlying business performance.
• Ineffective or costly marketing efforts may harm business and results of operations.
• Strategic investments or acquisitions could require significant management attention, disrupt business, and adversely affect financial results.
• Business depends on the continued efforts of senior management; loss of key executives could severely disrupt operations.
• Risk of labor disputes or additional compensation costs if employee basic salaries fail to meet local minimum standards (e.g., Hongcai Huang case).
• Intense competition for qualified and skilled employees.
• Lack of product liability and business insurance coverages exposes the company to uninsured losses.
• Exposure to greater than anticipated tax liabilities due to complex tax structure and uncertain interpretations by PRC tax authorities.
• Cybersecurity incidents could disrupt business operations, result in loss of critical information, and impact reputation.
• Potential intellectual property infringement claims, which may be expensive to defend and disrupt business.
• Management team's relative lack of public company experience could impair compliance with legal and regulatory requirements.
• Unfavorable fluctuations in raw material prices to suppliers could cause production delays or increase procurement costs.
• Lack of requisite approvals, licenses, or permits applicable to business, or failure to comply with PRC laws on leased property, could lead to fines or relocation.
• Restrictive covenants under long-term bank loans may limit operations; a default could adversely affect liquidity.
• Changes in China's economic, political, or social conditions or government policies could have a material adverse effect on business.
• Chinese regulatory authorities could disallow the corporate structure, leading to material changes in operations or value of securities.
• Reliance on dividends from PRC subsidiaries for cash and financing requirements; limitations on their ability to pay dividends could adversely affect business.
• PRC regulation of loans and direct investment by offshore holding companies may restrict using IPO proceeds for PRC subsidiaries.
• Uncertainties and quick changes in PRC laws and regulations, and potential for the Chinese government to exert more control over overseas offerings and foreign investment.
• Substantial influence of the Chinese government over business conduct, with potential for intervention at any time.
• Difficulties for investors to bring actions against the company or its officers/directors in the U.S. or enforce judgments due to Cayman Islands incorporation and PRC operations.
• The Holding Foreign Companies Accountable Act (HFCA Act) and related regulations pose delisting risks if the PCAOB cannot inspect the auditor for two consecutive years.
• Fluctuations in exchange rates (RMB/USD) could materially affect results of operations and investment value.
• Governmental control of currency conversion may limit the ability to utilize net revenues effectively.
• Failure to make adequate contributions to various employee benefit plans as required by PRC regulations may subject the company to penalties.
• CSRC filing is required for this offering under New Overseas Listing Rules; uncertainty exists regarding approval and potential sanctions for non-compliance.
• M&A Rules and other PRC regulations could make future acquisitions more difficult.
• Subject to a variety of laws and obligations regarding data security, cybersecurity, privacy, and personal information protection in China; non-compliance could lead to penalties.
• PRC regulations relating to offshore investment activities by PRC residents (SAFE Circular 37) may limit capital increases or profit distribution.
• Failure to comply with PRC regulations regarding employee stock incentive plans may subject participants or the company to fines.
• Classification as a PRC resident enterprise for tax purposes could result in unfavorable tax consequences for the company and non-PRC shareholders.
• Uncertainty regarding PRC tax reporting obligations for certain indirect transfers of equity interests.
• Risk of potential impact on business due to tax compliance issues in equity transfers of PRC subsidiaries (lack of tax certificates for past transfers).
• No public market for shares prior to this offering; active trading market may not develop or be sustained.
• Shares may be thinly traded, making it difficult to sell at or near ask prices.
• Chairman Mr. Weixiong Tan will control more than 50% of voting power, potentially conflicting with other shareholders' interests.
• Lack of research or negative reports from securities analysts could cause stock price and trading volume to decline.
• Market price for ordinary shares may be volatile due to broad market and industry factors, and perception of U.S.-listed Chinese companies.
• Immediate and substantial dilution for new investors due to offering price being substantially higher than pro forma net tangible book value per share.
• Volatility in share price may subject the company to securities litigation.
• Management has broad discretion in the use of net proceeds, which may not be used effectively.
• No cash dividends are anticipated in the foreseeable future.
• Difficulties in protecting shareholder interests due to Cayman Islands law providing less protection than U.S. laws.
• Exemptions as a foreign private issuer and emerging growth company mean less extensive and timely disclosures and potentially less protection for investors.
• Potential delisting from Nasdaq Capital Market if initial or continued listing requirements are not met.
• As a controlled company, the company may rely on exemptions from certain Nasdaq corporate governance requirements.
• Potential classification as a Passive Foreign Investment Company (PFIC) could result in adverse U.S. federal income tax consequences for U.S. taxpayers.
• The board of directors may refuse or delay the registration of share transfers in certain circumstances.
• Increased costs as a public company, particularly after ceasing to qualify as an emerging growth company.
• Obligation to develop and maintain proper and effective internal control over financial reporting (Section 404); failure could adversely affect investor confidence.
• If a limited number of participants purchase a significant percentage of the offering, the effective public float may be smaller, leading to price volatility and potential litigation.

Future Outlook

The company plans to expand into distributing high-quality products with intellectual property rights or exclusive distribution rights, expand into international markets by distributing TCMD to Europe and introducing foreign medicines, and implement a digital intelligence strategy to enhance marketing and operational efficiency through big data analysis and IT technology. It also intends to increase its depth and strength in tonic products and build a series of medicinal liquor products. The company expects overall selling expenses to increase in the foreseeable future in line with continued business expansion.

Management Comments

• Our professional marketing team with rich experience and a stable structure is the cornerstone for the Company to achieve its strategic development and revenue growth goals.
• We believe that with our well-developed sales and marketing network and experienced and outstanding team, we are fully capable of occupying a place in the market competition.
• We intend to keep any future earnings to re-invest in and finance the expansion of our business, and we do not anticipate that any cash dividends will be paid in the foreseeable future.

Industry Context

The company operates in China's medical and health products market, particularly traditional Chinese medicine (TCMD). This market is experiencing significant growth driven by an aging population, increasing chronic diseases, rising per capita disposable income, and improved health awareness. Government policies strongly support the development of TCMD, including its integration into the medical insurance catalogue and promotion of primary-level penetration and innovation. The overall TCMD market size declined after 2017 but has recovered in the past two years due influenced by price increases and reduction of lower-price medicines. The chemical medicine market is also growing steadily, with a significant increase in dermatology medicine use, driven by similar demographic and economic factors, and the rise of online pharmacies. The industry concentration for TCMD production and pharmaceutical distribution is increasing, but the retail pharmacy market remains fragmented.

Comparison to Industry Standards

• The company competes with well-known enterprises in the medicine distribution industry such as Jointown Pharmaceutical Group Co., Ltd, China National Accord Medicines Corporation Ltd, and Qingdao Baheal Medical Inc.
• It also competes with traditional Chinese medicine manufacturers that have their own distribution channels, including China Beijing Tongrentang Group Co., Ltd., Yunnan Baiyao Group, China Resources Sanjiu Medical & Pharmaceutical Co., Ltd, and Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.
• The company's low bad debt ratio is below the industry level, indicating effective credit management.
• The TCMD market in China is characterized by a large number of small and medium-sized enterprises (over 80% of Chinese patent medicine enterprises), suggesting HengHong's scale might be typical or slightly larger than average for this segment, but smaller than leading national players.

Management Changes

Corporate Governance

Legal Proceedings

• Currently not a party to any material legal or administrative proceedings.
• A labor dispute arbitration request was filed in December 2024 by Hongcai Huang against HengCheng and its former parent company, seeking RMB 343,988 (approximately $47,126) for economic compensation, unpaid annual leaves, and overtime wages. A hearing was held on February 19, 2025, with a verdict pending.

Related Party Transactions

• Guangdong Hengcheng Pharmaceutical Co., Ltd. (GDHC), controlled by the Chairman's family, accounted for 100% of total product purchases in 2023 and 96.5% in 2024.
• GDHC also accounted for 100% of the total balance of advance payment to supplier as of December 31, 2024.
• Shaanxi Hengcheng Pharmaceutical Co., Ltd. (SXHC), controlled by the Chairman's family, is the customer for promotion and marketing services, generating RMB 11,760,295 in 2024.
• Loans and advances from CEO Mr. Wei Zhao amounted to US$ 400,010 (RMB 2,919,793) as of December 31, 2024, to fund working capital needs, interest-free and due upon IPO completion or within 360 days.
• Amounts due to GDHC, Zhanjiang HengHong, and Zhanjiang Fengyuan related to the Reorganization totaled RMB 1,939,700, RMB 4,793,338, and RMB 849,377 respectively as of December 31, 2024, all interest-free and settled by the date of the prospectus.
• The Chairman, Mr. Weixiong Tan, and his immediate family member, Ms. Jianwen Su, along with related entities, provided joint guarantees for the company's bank borrowings.

Stakeholder Impact

• Shareholders: Potential for significant dilution from the IPO, limited protection due to controlled company status and Cayman Islands jurisdiction, and risks from declining financial performance and regulatory uncertainties.
• Employees: Risk of labor disputes if basic salaries do not meet local minimum standards, but the company states it maintains good working relationships and has made adequate benefit payments.
• Customers: Potential impact from product safety claims, changes in product offerings, and shifts in distribution channels (e.g., increased online focus).
• Suppliers: High concentration risk with GDHC, which could impact supply stability or pricing if the relationship changes.
• Creditors: Risk from restrictive covenants on bank loans and the loan becoming callable due to reorganization, potentially affecting liquidity.

Next Steps

• Complete the initial public offering and list on the Nasdaq Capital Market.
• Expand into the distribution of high-quality products with intellectual property rights or exclusive distribution rights.
• Expand into the international market, focusing on TCMD distribution to Europe and introducing foreign innovative medicines.
• Build a digital platform/system covering all business management areas, utilizing IT technology for intelligent applications.
• Recruit and reserve outstanding international talents.
• Address the CSRC feedback on the offering filing submitted on December 30, 2024.
• Manage the callable long-term bank loan and ensure compliance with covenants or satisfactory arrangements with the lender.
• Comply with Section 404 of the Sarbanes-Oxley Act for internal control over financial reporting by December 31, 2026.

Key Dates

Recommendation

The company is undergoing an IPO with significant capital raise plans for strategic growth initiatives, including new product development, international expansion, and digital transformation. However, the recent financial performance shows a notable decline in both revenue and net income, coupled with a high concentration of risks related to its China-based operations, regulatory uncertainties (CSRC approval, HFCA Act), and reliance on related parties. The 'controlled company' status also limits minority shareholder protections. A seasoned investor would likely 'hold' due to the high speculative nature, waiting for clearer signs of financial stabilization, successful execution of growth strategies, and resolution of regulatory uncertainties before considering a 'buy' or 'sell' position. The current financial downturn and extensive risks outweigh the potential upside from the IPO and growth plans in the short term.

Keywords

Pharmaceutical Distribution, Traditional Chinese Medicine, TCMD, Medical Products, China Healthcare, IPO, Nasdaq Listing, SEC Filing, Chinese Economy, Regulatory Risk, Corporate Governance, Foreign Private Issuer, Emerging Growth Company, Controlled Company, Hainan, Cross-border Data Transfer, Cybersecurity, HFCA Act, Related Party Transactions, Capital Raise, Market Volatility